Johnson & Johnson (JNJ) is Brightworth’s 6th Largest Position

Brightworth raised its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,809 shares of the company’s stock after acquiring an additional 1,297 shares during the quarter. Johnson & Johnson makes up 2.1% of Brightworth’s holdings, making the stock its 6th biggest position. Brightworth’s holdings in Johnson & Johnson were worth $9,474,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Beach Investment Management LLC. lifted its stake in shares of Johnson & Johnson by 1,256.6% during the 2nd quarter. Beach Investment Management LLC. now owns 286,648 shares of the company’s stock valued at $37,921,000 after buying an additional 265,518 shares in the last quarter. Signature Financial Management Inc. lifted its stake in shares of Johnson & Johnson by 17.3% during the 2nd quarter. Signature Financial Management Inc. now owns 13,336 shares of the company’s stock valued at $1,758,000 after buying an additional 1,967 shares in the last quarter. United Asset Strategies Inc. lifted its stake in shares of Johnson & Johnson by 3.6% during the 2nd quarter. United Asset Strategies Inc. now owns 5,468 shares of the company’s stock valued at $723,000 after buying an additional 192 shares in the last quarter. Tortoise Investment Management LLC lifted its stake in shares of Johnson & Johnson by 3.3% during the 2nd quarter. Tortoise Investment Management LLC now owns 4,349 shares of the company’s stock valued at $575,000 after buying an additional 139 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC lifted its stake in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 134,022 shares of the company’s stock valued at $17,730,000 after buying an additional 2,117 shares in the last quarter. Hedge funds and other institutional investors own 67.24% of the company’s stock.

How to Become a New Pot Stock Millionaire

JNJ has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 price target on the stock in a research note on Thursday, April 5th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price target on the stock in a research note on Tuesday, January 23rd. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 10th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $144.03.

In other news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.22% of the stock is owned by corporate insiders.

Johnson & Johnson stock opened at $130.62 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. The company has a market cap of $349,930.91, a P/E ratio of 17.89, a PEG ratio of 2.07 and a beta of 0.74. Johnson & Johnson has a 1-year low of $120.95 and a 1-year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. Johnson & Johnson’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.58 EPS. research analysts expect that Johnson & Johnson will post 8.11 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://weekherald.com/2018/04/15/johnson-johnson-jnj-is-brightworths-6th-largest-position.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply